WEBCAST Novel Induction Options in AML

Assessing the Implications for HCT-Eligible Patients

In this activity, experts in acute myeloid leukemia (AML) guide you through the science that supports the rapid integration of newer induction regimens into the care of AML patients who are eligible for hematopoietic stem cell transplantation (HCT), while offering expert thoughts on what a more diverse selection of induction options means for patients who have the greatest need for alternative treatments, including those with high-risk disease, older individuals who are fit for intensive therapy, or patients with molecular aberrations/mutations conferring a poor prognosis.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, bone marrow transplant (BMT) specialists, BMT nurse specialists, and other clinicians involved in the management of patients with AML.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  1. Summarize the current role and challenges of HCT and induction therapy in AML, including in elderly and high-risk patients
  2. Describe new evidence on novel induction strategies in AML such as novel cytotoxic or targeted strategies
  3. Select personalized, safe induction strategies for transplant eligible patients with AML who may not benefit from induction with standard 7+3
Additional information

Contact

Name: 
Megan Cowell
Phone Number: 
+1 (405) 735-7206
Email: 
[email protected]
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
05/01/2017
Course expires: 
12/31/2018
Cost:
$0.00

Planning Director:  Mary Horowitz

No one in control of content has any relevant financial relationships to disclose.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by independent medical educational grants from Astellas, Merck & Co., Inc., and Shire.  This session is open to all registrants of the 2018 BMT Tandem Meetings.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.